I already posted all my thoughts concerning revenue from the GRWG partnership and from fees/royalties from licensees they've worked with who are scaling up their businesses now (including Boone Labs, btw). The fruits of their labor are likely show up in due time, imo. I don't compare BLDV to big board stocks or expect big board numbers - I have it picked out from the swamp of subpennies as one of no more than two or three that are real companies, profitable, don't have debt instruments, and have very low liabilities. It's trading for 8 one hundredths of a penny per share, not competing with Tilray. As subpennies go, it's better than pretty much all of them imo. So from that perspective, as a best-in-class ticker compared to its subpenny peers, I personally like the risk/reward. The whole industry is not going downhill - the market tanked nearly all sectors, but cannabis stocks rebounded in a big way Thursday and Friday, and there will be a mad dash to buy them up whenever a bottom seems confirmed. Lots of institutional buys this quarter in cannabis ETFs, so that's the writing on the wall. Germany will legalize soon as will the rest of Europe, and the USA is likely to pass safe banking sooner than later. There will be more market volatility of course, but personally I like to buy low and sell high, and I think there's a high probability that's a likely outcome with cannabis stocks from these levels. One day OTCs will get hot again, probably not for a while, but when that happens I like BLDV compared to anything else at this pps/market cap. When the OTCs run, they all move up, but of trips/low 00s stocks, only BLDV and one other ticker I'm aware of won't get crushed by convertible debt on any bounce. But I was responding to your statement about pumpers. There are no pumpers here. If BLDV loses investors, that's great - an opportunity to buy cheaper. If they turn things around, great - sell higher. All the permutations of how the pps works out in the near term are A-ok with me.
News 
Market Data 
Discover 
